Northern Ireland to Implement Indefinite Ban on Puberty Blockers for Under-18s

Northern Ireland is set to introduce a permanent prohibition on the provision or distribution of puberty blockers to individuals under the age of 18. These medications function by inhibiting hormone release and are sometimes prescribed to minors exploring their gender identity. In May, the Conservative government implemented stricter regulations concerning these drugs, instituting an urgent prohibition on their prescription by private and European medical professionals. This provisional ban was subsequently extended to Northern Ireland in August. Currently, all four Executive parties within Stormont have cast votes in favor of establishing this ban as permanent. According to BBC News NI, this action is anticipated to align with a broader declaration expected across other regions of the UK later this week. Deputy First Minister Emma Little-Pengelly stated on X that this represents “the right approach, informed by medical and scientific advice.” She further emphasized, “The protection and safety of our young people must be paramount.” Green Party Councillor Anthony Flynn asserted that the Executive had not adequately supported LGBTQ+ individuals. He stated that the Executive had committed to a strategy “since 2007 to address the inequalities that our community face but it has never been delivered.” He continued, “When this temporary ban was announced in the summer, we and many activists argued that the executive should release the evidence that informed this decision. Now that the ban has been made indefinite, it should be released.” He also mentioned that his party felt “particularly disappointed” with Sinn Féin and the Alliance Party, who, in his view, offered “much lip service to LGBTQ+ equality but have yet to use their 26 years in government to improve our lives in any meaningful way.” Within Northern Ireland, puberty blockers were exclusively accessible via NHS prescription for individuals under 18, specifically for those minors who had been admitted to the Child and Adolescent Mental Health Services Gender Identity Service endocrine pathway before March 2020. It is understood that children currently undergoing treatment through this medical pathway will maintain their access to care. Furthermore, hormone suppressors will continue to be accessible for patients utilizing these medications for alternative purposes, including conditions like precocious puberty. The decision to prohibit puberty blockers follows a report on children’s gender services, known as the Cass Review, which indicated “gaps in evidence” concerning these medications. This review, spearheaded by prominent paediatrician Dr Hilary Cass, led the previous government to forbid the administration of puberty blockers to under-18s exploring their gender identity – a policy subsequently endorsed by the Labour party upon their electoral victory.